Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study by Valerio, Luca et al.








Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism:
Analysis From a Prospective Multicenter Cohort Study
Valerio, Luca ; Barco, Stefano ; Jankowski, Marius ; Rosenkranz, Stephan ; Lankeit, Mareike ; Held,
Matthias ; et al
Abstract: BACKGROUND Few data are available on the long-term course and predictors of quality of
life (QoL) following acute pulmonary embolism (PE). RESEARCH QUESTION What are the kinetics
and determinants of disease-specific and generic health-related QoL 3 and 12 months following an acute
PE? STUDY DESIGN AND METHODS The Follow-up after Acute Pulmonary Embolism (FOCUS)
study prospectively followed up consecutive adult patients with objectively diagnosed PE. Patients were
considered for study who completed the Pulmonary Embolism Quality of Life (PEmb-QoL) questionnaire
at predefined visits 3 and 12 months following PE. The course of disease-specific QoL as assessed using the
PEmb-QoL and the impact of baseline characteristics using multivariable mixed effects linear regression
were studied; also assessed was the course of generic QoL as evaluated by using the EuroQoL Group
5-Dimension 5-Level utility index and the EuroQoL Visual Analog Scale. RESULTS In 620 patients
(44% women; median age, 62 years), overall disease-specific QoL improved from 3 to 12 months, with a
decrease in the median PEmb-QoL score from 19.4% to 13.0% and a mean individual change of -4.3%
(95% CI, -3.2 to -5.5). Female sex, cardiopulmonary disease, and higher BMI were associated with worse
QoL at both 3 and 12 months. Over time, the association with BMI became weaker, whereas older
age and previous VTE were associated with worsening QoL. Generic QoL also improved: the mean ±
SD EuroQoL Group 5-Dimension 5-Level utility index increased from 0.85 ± 0.22 to 0.87 ± 0.20 and
the visual analog scale from 72.9 ± 18.8 to 74.4 ± 19.1. INTERPRETATION In a large cohort of
survivors of acute PE, the change of QoL was quantified between months 3 and 12 following diagnosis,
and factors independently associated with lower QoL and slower recovery of QoL were identified. This
information may facilitate the planning and interpretation of clinical trials assessing QoL and help guide
patient management. CLINICAL TRIAL REGISTRATION German Clinical Trials Registry (Deutsches
Register Klinischer Studien: www.drks.de); No.: DRKS00005939.
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BACKGROUND: Few data are available on the long-term course and predictors of quality of life
(QoL) following acute pulmonary embolism (PE).
RESEARCH QUESTION: What are the kinetics and determinants of disease-specific and generic
health-related QoL 3 and 12 months following an acute PE?
STUDY DESIGN AND METHODS: The Follow-up after Acute Pulmonary Embolism (FOCUS)
study prospectively followed up consecutive adult patients with objectively diagnosed PE.
Patients were considered for study who completed the Pulmonary Embolism Quality of Life
(PEmb-QoL) questionnaire at predefined visits 3 and 12 months following PE. The course of
disease-specific QoL as assessed using the PEmb-QoL and the impact of baseline charac-
teristics using multivariable mixed effects linear regression were studied; also assessed was the
course of generic QoL as evaluated by using the EuroQoL Group 5-Dimension 5-Level utility
index and the EuroQoL Visual Analog Scale.
RESULTS: In 620 patients (44% women; median age, 62 years), overall disease-specific QoL
improved from 3 to 12 months, with a decrease in the median PEmb-QoL score from 19.4% to
13.0% and a mean individual change of –4.3% (95% CI, –3.2 to –5.5). Female sex, cardiopul-
monary disease, and higher BMI were associated with worse QoL at both 3 and 12 months. Over
time, the association with BMI became weaker, whereas older age and previous VTE were
associated with worsening QoL. Generic QoL also improved: the mean SD EuroQoLGroup 5-
Dimension 5-Level utility index increased from 0.85 0.22 to 0.87 0.20 and the visual analog
scale from 72.9  18.8 to 74.4  19.1.
INTERPRETATION: In a large cohort of survivors of acute PE, the change of QoL was quantified
between months 3 and 12 following diagnosis, and factors independently associated with lower
QoL and slower recovery of QoL were identified. This information may facilitate the planning
and interpretation of clinical trials assessing QoL and help guide patient management.
CLINICAL TRIAL REGISTRATION: German Clinical Trials Registry (Deutsches Register Kli-
nischer Studien: www.drks.de); No.: DRKS00005939. CHEST 2021; 159(6):2428-2438
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The annual incidence of acute pulmonary embolism
(PE) continues to increase,1-4 while early mortality
related to this condition is progressively decreasing.5-7
Consequently, and as many survivors report long-lasting
and potentially severe symptoms or disability,8 ensuring
a good functional status and quality of life (QoL) over
the long term following PE will present an important
task for the years to come.
Patient-centered outcomes such as self-reported health-
related QoL form the basis of health care quality
assessment,9 and their inclusion as outcome measures
in clinical trials is now recommended to guide shared
decisions on health policy-making.10 In the case of
acute PE, assessment tools for generic (non-PE-
specific) health-related QoL have been applied in
registries and small-scale cohort studies of selected
populations.11,12 In addition, the Pulmonary Embolism
Quality of Life (PEmb-QoL) questionnaire was
developed13 and validated14 as a disease-specific
instrument to measure QoL in survivors of acute PE.
Disease-specific instruments for the assessment of
health-related QoL are a valuable addition to generic
standardized tools to identify and monitor “quality
dimensions” of concern and compare results across
studies on patients with the same condition.15 The
application of PEmb-QoL in cross-sectional studies16,17
and prospective cohort studies of selected populations11
has generated the hypothesis that complete functional
recovery, as reflected in several QoL dimensions, may
require several months, or possibly not occur at all,
thus adding further support to the clinical and
epidemiologic relevance of the “post-PE syndrome.”18
However, to the best of our knowledge, neither the
temporal course of QoL and its individual dimensions
nor their association with baseline clinical
characteristics have thus far been the object of
investigation in prospectively studied large cohorts of
survivors of acute PE.
Take-home Points
Study Question: What are the kinetics and de-
terminants of disease-specific and generic health-
related QoL 3 and 12 months following an acute PE?
Results: Both disease-specific and generic health-
related QoL improved between 3 and 12 months
following an acute PE, with disease-specific QoL
lower in women and those with higher BMI or pre-
existing cardiopulmonary disease, and declining
over time in older patients and those with a history of
VTE.
Interpretation: Our data may be relevant to guide
management and assess interventions in the context
of a more comprehensive and holistic approach to
patients recovering from acute PE.
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The Follow-up after Acute Pulmonary Embolism
(FOCUS) study19 is an ongoing prospective,
observational, multicenter study systematically
following up all-comers with symptomatic acute PE;
follow-up comprises a standardized comprehensive
program of clinical, echocardiographic, functional, and
laboratory testing over a 2-year period. The aim of the
current analysis was to dissect the indicators of disease-
specific and generic health-related QoL at 3- and 12-
month follow-up following the diagnosis of PE and to
identify baseline characteristics that may predict
persisting symptoms or functional limitation.
Study Design and Methods
Study Population
FOCUS (German Clinical Trials Registry number DRKS00005939) has
included consecutive unselected patients with a confirmed diagnosis of
acute symptomatic PE.19 Patients were enrolled at 17 large-volume
centers across Germany and are being followed up over a 2-year
period with a predefined visit plan; the plan includes clinical,
functional, laboratory, and echocardiographic examinations as well as
health status assessments at five prespecified visits (upon enrollment,
at hospital discharge, and at 3, 12, and 24 months). The study
protocol does not mandate diagnostic or therapeutic decisions;
patients are treated according to the standard of care at the
participating centers and in adherence to current guidelines.8,20
Patients with asymptomatic PE or previously diagnosed chronic
thromboembolic pulmonary hypertension were excluded from the
study.19
The current analysis included patients who had completed, as of March
2020, at least one item in all numeric dimensions of the 40-item PEmb-
QoL questionnaire both at the 3-month and the 12-month visit.
Assessment of QoL
The PEmb-QoL questionnaire used in the current analysis was
developed in 2009 to selectively measure disease-specific health-
related QoL following PE.14 The questionnaire was translated from
the English version to German. The PEmb-QoL has been validated
and shown to be a reliable disease-specific questionnaire for patients
with PE.17,21 It includes nine questions (e-Table 1). Seven of these
questions assess health-related QoL, covering six numeric
“dimensions”: (1) frequency of complaints (question 1), (2) limitation
of activities in daily life (question 4), (3) work-related problems
(question 5), (4) social limitations (question 6), (5) intensity of
complaints (questions 7 and 8), and (6) emotional complaints
(question 9). The percentage scores obtained in each one of the six
dimensions are averaged to obtain an overall percentage score (0-100),
aiming to reflect the overall QoL. Of note, higher scores indicate
worse QoL. Although the remaining two questions do not contribute
to the overall score, they provide descriptive information on the time
of day when the symptoms appear and the patient’s perceived current
cardiopulmonary function compared with 1 year earlier.13
Generic, nondisease-specific health-related QoL was assessed by using
the EuroQoL Group 5-Dimension 5-Level (EQ-5D-5L) questionnaire
and its corresponding visual analog scale.22 The EQ-5D-5L assesses
health-related QoL descriptively in five dimensions: (1) mobility, (2)
self-care, (3) usual activities, (4) pain and discomfort, and (5) anxiety
and depression. The information is integrated into an overall index
that ranges from 0 to 1 and is calculated based on country-specific
reference value sets. In this index, and in contrast to the PEmb-QoL
score, higher values indicate better health. The EQ-5D-5L health
index was calculated with the value set for Germany.
The EuroQol Visual Analogue Scale ranges from 0 to 100, with higher
scores indicating better health.
Clinical Characteristics at Baseline
The clinical features at the time of index PE considered for association
with QoL were selected based on their association with the course of
generic indicators of QoL, or the PEmb-QoL, in previous
studies.11,12,23,24 They included sex, age, BMI, chronic heart or lung
disease, cancer, previous VTE, smoking status, a major transient/
reversible risk factor for the index PE event, and low-risk index PE.
Chronic cardiopulmonary disease included chronic heart failure,
coronary artery disease, or chronic pulmonary disease. Previous
VTE was defined as history of deep lower extremity vein thrombosis,
PE, or arm vein thrombosis. Major transient/reversible risk factors
for index PE were defined as major surgery, trauma, or
immobilization within 30 days preceding the diagnosis. Low-risk PE
was defined as an episode not accompanied by hemodynamic
instability, clinical, imaging, or laboratory indicators of acute right
ventricular pressure overload and dysfunction, or serious
comorbidity or any other condition that might adversely affect early
prognosis.20
Statistical Methods
Categorical variables are presented as frequencies and percentages;
continuous variables are presented as medians with first and third
quartiles (interquartile range [IQR]), or means with the
corresponding SD, according to their distribution. Mean differences
with 95% CIs obtained from paired Student t tests (provided that the
differences were normally distributed) were used to calculate
intraindividual changes in overall and dimension-specific PEmb-QoL
score, EQ-5D-5L utility index, and EuroQoL Visual Analogue Scale
from 3 to 12 months; they were also used to study the univariate
association between baseline clinical characteristics and changes in
overall PEmb-QoL score from 3 to 12 months. A mixed effects
model with random intercepts was used to investigate the association
between baseline clinical characteristics and the overall PEmb-QoL
score at 3 and 12 months. To evaluate whether the associations
changed over time, the model included interaction terms between
each clinical characteristic and time (defined as the two time points,
3 months [used as reference level] and 12 months). The proportion
of patients attaining a minimal clinically important difference of 15
points in the overall PEmb-QoL score as derived from a relatively
healthy population of patients with acute PE was also calculated.25
Two-tailed P values < .05 were considered significant. R version
3.6.1 (R Foundation for Statistical Computing) with the tidyverse
packages was used for data analysis.
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Results
Study Population
The current analysis focused on 620 patients who
completed the PEmb-QoL questionnaire at both the
3- and the 12-month follow-up visit of the 799
patients with complete follow-up until 12 months.
The median age of patients included in the analysis
was 62 years (IQR, 49-73 years), and 43.9% were
women (Table 1). The index PE followed a major
transient risk factor in 141 (22.7%) patients and was
classified as low risk in 130 (21.0%) patients.
Comparison of the baseline characteristics of the
study patients with a complete PEmb-QoL
assessment vs without (n ¼ 179) (e-Table 2) revealed
no relevant differences.
TABLE 1 ] Baseline Characteristics of Study Patients (N ¼ 620)
Variable Value
Patient demographic characteristics
Women, n/N (%) 272/620 (44)
Age, median (IQR), y 62 (49-73)
White ethnicity, n/N (%) 613/620 (99)
Vital signs and other clinical parameters at diagnosis of pulmonary embolisma
Systolic/diastolic BP, mean  SD, mm Hg 136.7  21.8/81.6  13.2a
Heart rate, median (IQR), beats/min 87.5 (74.0-100.0)a
Oxygen saturation, median (IQR), % 96.0 (93.0-97.5)a
Respiratory rate, median (IQR), breaths/min 17 (15-20)a
Hemodynamic collapse, n/N (%) 16/620 (2.6)
Pulmonary embolism risk class,b n/N (%)
Low risk 130/620 (21)
Intermediate risk 474/620 (76)
High risk 16/620 (2.6)
BMI, median (IQR), kg/m2 28.3 (25.0, 32.3)
Glomerular filtration rate < 50 mL/min, n/N (%) 94/613 (15)
Risk factors for thrombosis and pulmonary embolism, n/N (%)
Cancer or myeloproliferative disease 49/620 (7.9)
Estrogen-containing medications 51/620 (8.2)
Pregnancy or lactation 2/620 (0.3)
Recent long-distance travel 58/620 (9.4)
Recent surgery or trauma (last 30 d) 79/620 (13)
Recent immobilization 105/620 (17)
History of VTE 133/620 (21)
Comorbidities and other risk factors, n/N (%)
Chronic pulmonary disease 78/620 (13)
Heart failure 25/620 (4.0)
Coronary artery disease 47/620 (7.6)
Arterial hypertension 324/620 (52)
Diabetes mellitus 64/620 (10)
Chronic liver disease 17/620 (2.7)
Chronic inflammatory disease 58/620 (9.4)
Smoking 101/620 (16)
IQR ¼ interquartile range.
aSystolic BP values were available in 593 of 620 patients, diastolic BP in 590/620 patients, heart rate in 594 of 620 patients, oxygen saturation in 517 of 620
patients, respiratory rate in 399 of 620 patients, BMI in 615 of 620 patients, and glomerular filtration rate in 613 of 620 patients.
bBased on the 2019 Guidelines of the European Society of Cardiology.8
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Disease-Specific Health-Related QoL
The distribution of the overall and dimension-specific
PEmb-QoL scores at 3 and 12 months is depicted in
Figure 1. The overall score decreased from a median of
19.4% (IQR, 7.1%-42.9%) to a median of 13.0% (IQR,
4.3%-37.4%). Because higher PEmb-QoL scores reflect
worse QoL and lower scores reflect better QoL, this
decrease indicated an overall improvement in QoL. The
mean intraindividual change in overall QoL between the
3- and 12-month follow-up was –4.3% (95% CI, –3.2 to
–5.5). The mean intraindividual change of the
dimension-specific PEmb-QoL is shown in Figure 2; an
improved QoL was observed in all six dimensions.
When applying a proposed estimate for minimal
clinically important difference of the PEmb-QoL score, a
clinically important improvement was observed in 118
of 620 (19.0%) patients and a clinically important
deterioration in 48 of 620 (7.7%) patients.
The descriptive question “at what time of the day are
your lung symptoms most intense?” was answered by
567 patients at both follow-up visits. At both 3 and
12 months, the most commonly reported response was
“never” (302 [53.3%] and 325 [57.3%] patients,
respectively), followed by “any time of the day” (77
[16.4%] and 95 [16.8%] patients). The descriptive
question “compared with 1 year ago, how would you
rate the condition of your lungs in general now?” was
answered by 585 patients at both 3 and 12 months; the
distribution of the responses is displayed in Figure 3. At
3 months, the most common response was “much
worse” or “somewhat worse” (201 [34.4%] patients),
followed by “about the same” (175 [29.9%]) and “much
better” or “somewhat better” (152 [26.0%]). Conversely,
at 12 months the most common response was “much
better” or “somewhat better” (324 [55.4%]), followed by
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Figure 1 – Distribution of dimension-specific and overall QoL as assessed by the PEmb-QoL score at 3 and 12 months. Tukey box plots depict the
median and interquartile range of dimension-specific and overall QoL as percentage of the maximum PEmb-QoL score. Values obtained at 3-month
(red boxes) and 12-month (blue boxes) follow-up following the diagnosis of PE are compared for a total of 620 patients. Higher PEmb-QoL scores
indicate lower QoL; accordingly, “lower” blue box plots compared with the red ones indicate an improvement in QoL for the respective dimension (or
the overall score) between month 3 and month 12. ADL ¼ activities of daily living; PEmb-QoL ¼ Pulmonary Embolism Quality of Life; QoL ¼ quality
of life.
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Baseline Characteristics and QoL Course
We performed a multivariable mixed effects regression
analysis to investigate the independent association
between characteristics at the time of PE diagnosis and
overall disease-specific QoL (PEmb-QoL) during follow-
up (n ¼ 615; five patients with missing data on BMI);
the results are summarized in Table 2. At both time
points, QoL was worse in women, patients with a higher
BMI, and patients with preexisting cardiopulmonary
disease. The interaction terms showed that older age and
history of VTE at baseline were associated with
worsening of QoL over time; conversely, the association
of higher BMI with QoL became weaker over time.
For descriptive purposes, the change in overall and
dimension-specific QoL from 3 to 12 months according
to selected clinical characteristics at the time of PE upon
univariate testing is reported in e-Figure 1.
Generic Health-Related QoL
The EQ-5D-5L analysis was conducted in a total of 597
patients with completed questionnaires at both visits.
The mean EQ-5D-5L index was 0.85  0.22 at the 3-
month visit, which improved to 0.87  0.20 at
12 months (paired Student t test, P ¼ .002). The
proportion of answers reporting “no problems” in any of
the five dimensions of the EQ-5D-5L questionnaire
increased from 63.2% at 3 months to 66.2% at
12 months, with the proportion of answers reporting
problems of any severity decreasing (slight, from
19.6% to 18.4%; moderate, from 11.6% to 10.8%; severe,
from 4.8% to 4.0%; and extreme, from 0.8% to 0.6%).
Figure 4 shows the distribution of these changes across
all five EQ-5D-5L dimensions. Finally, the EuroQol
Visual Analogue Scale (available in 608 patients)
increased from a mean of 72.9  18.8 points to 74.4 
19.1 points (paired Student t test for difference, P ¼
.022), also reflecting improved QoL.
Discussion
This analysis of the prospective FOCUS study provides
an outline of the level and long-term course of health-
related QoL, as estimated by using both the disease-
specific questionnaire PEmb-QoL and the generic
assessment tool EQ-5D-5L. Both disease-specific and
generic QoL improved between 3 and 12 months
following an acute PE. This improvement was observed
for all dimensions of PEmb-QoL and of EQ-5D-5L,

























Figure 2 – Intraindividual change in
quality of life as assessed by using the
Pulmonary Embolism Quality of Life
(PEmbQoL) score between 3- and 12-
month follow-up. The dark blue line
(mean value) and the blue ribbon (cor-
responding 95% CI) indicate the intra-
individual change in the PEmbQoL score
between month 12 and month 3 of
follow-up. They are plotted as a hexagon
to represent each one of the six PEmb-
QoL dimensions. Means and CIs were
calculated by using paired two-sided
Student t tests. For each dimension, the
scale from 0% to –11% indicates the
observed absolute difference in score
percentage points between 12 and
3 months. A negative difference indicates
improvement in quality of life between
the 3-month and 12-month follow-up.
ADL ¼ activities of daily living.
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status, and symptoms. Female sex, higher BMI, and
preexisting chronic cardiopulmonary disease were
associated with worse QoL at both 3 and 12 months.
Over time, the association with BMI became weaker, and
QoL declined in older patients and those with a history
of previous VTE.
In 620 patients enrolled in the ongoing multicenter
FOCUS study who had survived the acute phase of PE,
the mean individual improvement of overall disease-
specific QoL between the 3- and 12-month follow-up
following PE was 4.3 percentage points (95% CI, 3.2-5.5)
in the PEmb-QoL questionnaire. This finding is
considerably lower than the mean group improvement
of 12.1 percentage points reported in the same follow-up
period (from month 3 to month 12 following an acute
PE) in a previous study on 100 patients at five Canadian
hospitals.11 This difference could be explained by the
strict selection criteria of that study, which excluded
patients with severe comorbidities, resulting in a low
prevalence of potential contributors to a poor health
status in the acute phase (at baseline). These include
older age (mean age of 50 years vs 59.7 years of our
study), previous VTE (excluded by Kahn et al11; present
in 21.5% of the patients in our study), and smoking
(7% vs 16.3% in our study).
Beyond the overall PEmb-QoL score, the time course of
individual PEmb-QoL dimensions has not been
previously studied. The validation study of PEmb-QoL
reported the cross-sectional dimension-specific scores in
90 patients a median of 38 months (range, 10-
91 months) following the index PE episode14 and found
a distribution of the dimension-specific scores similar to
our findings at 12 months. This suggests that the scores
in all individual dimensions and, consequently, the
patient’s “overall” disease-specific QoL may remain
relatively stable in the first 12 months following an
acute PE.
Previously reported associations between clinical
characteristics at the time of the index PE and
subsequent disease-specific QoL may not be directly
comparable with our findings, as those studies included
evaluation of QoL between hospital admission for the
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Figure 3 – Perceived change in the patients’ cardiopulmonary function at 3 and 12 months. Alluvial plot showing the percentage of each answer to
question 3 of the Pulmonary Embolism Quality of Life (PEmb-QoL) score (“perceived change in cardiopulmonary function compared with 1 year
earlier”) in patients who answered the question at both visits (n ¼ 585). Response at 3 months following the index PE refers to comparison with the
condition 9 months prior to the index PE; response at 12 months refers to the comparison with the condition immediately prior to the index PE.
“Worse” is defined as a response “much worse” or “somewhat worse”; “better,” as a response “much better” or “somewhat better.” “No problems 1 year
earlier” corresponds to the response “I did not have any problems with my lungs” (e-Table 1).
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may lead to QoL estimates more strongly affected by the
early course of the disease and specific circumstances
related to acute-phase treatment of the index event (eg,
admission to an ICU, hospitalization in a general ward,
early discharge). For example, the study by Kahn et al11
reported an association of female sex and higher BMI,
but not of lung disease or smoking status, with worse
QoL following PE. It is likely that these latter
associations were “diluted” by the inclusion of the QoL
measurement at baseline or 1 month and may not
become apparent until after the first 3 months, as was
the case in the current study.
In the same context, it should be noted we found no
association between the PE risk class in the acute phase8
and QoL at follow-up. This fact supports the notion that
risk stratification is important to assess only the early
prognosis of acute PE, and it may also suggest that the
deconditioning often observed in the long-term follow-
up of PE can occur regardless of the initial PE severity, if
the patient does not (or cannot) resume a healthy
lifestyle.26,27 We also found no association between
active cancer at baseline and either the level of disease-
specific QoL or its change over time. This finding is
consistent with previous cross-sectional analyses that
applied the PEmb-QoL score to smaller
populations,14,16,17 and it may reflect, among others, the
fact that patients with advanced cancer are
(understandably) underrepresented in studies focusing
on long-term QoL.
In the current analysis, the course of generic,
nondisease-specific health-related QoL from 3 to
12 months as assessed by using the EQ-5D-5L utility
index and the EuroQol Visual Analog Scale
substantially paralleled the improvement observed in
disease-specific QoL. This improvement encompassed
all EQ-5D-5L dimensions with the exception of “self-
care,” which displayed a lower burden than the other
dimensions already at the 3-month follow-up. In a
previous analysis of multicountry prospective registry
data, the course of the EQ-5D-5L utility index was
comparable to our findings, whereas its absolute levels
differed according to country; those observed in
German-speaking countries were similar to those we
report.12
Our findings may have direct implications for clinical
practice and future research. Following management
decisions after risk stratification of acute PE, the first
follow-up evaluation at 3 months represents a critical
milestone for decisions regarding the duration of
anticoagulation and possible additional testing for late
sequelae of PE.8,28 We provide the first estimate of
clinically important deterioration of disease-specific QoL
from 3 to 12 months (7.7% of the patients in the study
cohort). Although based on an estimate of minimal
clinically important change derived in relatively healthy
patients with acute PE, the generalizability of which
needs confirmation, this deterioration may provide the
basis of a clinical tool to identify patients who are
experiencing late PE sequelae in a standardized way. The
associations between baseline characteristic and
subsequent course of QoL that were identified in the
TABLE 2 ] Multivariable Mixed Effects Regression
Analysis of the Association Between Clinical
Characteristics at the Time of Index PE and
Overall Disease-Specific Quality of Life at 3
and 12 Months
Characteristic b (95% CI)
Time (12 mo vs 3 mo) –7.4 (–15.2, 0.4)
Women (vs men) 7.9b (3.3, 12.6)
Age (per 10-y increase) –0.1 (–1.6, 1.5)
BMI (per kg/m2 increase) 0.8b (0.4, 1.2)
Chronic cardiopulmonary disease 9.6b (3.5, 15.6)
Cancer 3.3 (–5.4, 12.1)
Previous VTE –4.5 (–10.1, 1.2)
Smoking 0.3 (–6.2, 6.8)
Major surgery, trauma, or
immobilizationa
–0.8 (–6.4, 4.8)
Low-risk (vs intermediate- or
high-risk) index PE
3.1 (–2.9, 9.0)
Women  time 0.5 (–1.8, 2.9)
Age (per 10-y increase)  time 1.0b (0.5, 2.0)




Cancer  time –2.0 (–6.4, 2.4)
Previous VTE  time 3.0b (0.2, 5.9)
Smoking  time 3.1 (–0.1, 6.4)
Major surgery, trauma, or
immobilization  time
1.5 (–1.3, 4.3)
Low-risk index PE  time 0.5 (–2.5, 3.6)
The analysis was conducted on 615 patients with available data. Positive
coefficients (95% CI) indicate worse overall disease-specific quality of life
as estimated by the Pulmonary Embolism Quality of Life score compared
with the reference level for each variable. In the interaction terms, time
consists of the two time points (3 months [reference level] and 12 months),
with positive coefficients indicating that the corresponding variable is
associated with worsening quality of life over time. PE ¼ pulmonary
embolism.
aWithin the 30 days preceding the diagnosis.
bP < .05.
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current study may be used by clinicians to better
recognize those patients who may require additional
testing and monitoring or changes in treatment. The use
of quantitatively validated patient-reported outcomes as
effectiveness end points in clinical trials is now
recommended by both the US Food and Drug
Administration29 and the European Agency for the
Evaluation of Medicinal Products.30
The current analysis has limitations. FOCUS is a
prospective cohort study of patients with PE. Because
we did not include a control study population without
PE, we cannot draw conclusions on an independent
association of PE with QoL; our findings are rather
meant to provide estimates of the temporal course of
QoL specific for this patient population. Because not all
patients completed the PEmb-QoL questionnaires at
both visits, selection bias against older patients and
those experiencing chronic diseases cannot be
excluded. However, < 25% of the patients in the
current study were excluded from analysis because of
missing questionnaire responses, and the rate of
chronic disease in the remaining patients was similar to
that reported in previous prospective studies of
consecutive patients with PE.31 Lastly, the racial and
ethnic composition of the FOCUS cohort was relatively
homogeneous. Care should be taken in generalizing
our findings to more ethnically diverse populations.
Interpretation
In a large cohort of survivors among unselected
patients treated for acute PE, both disease-specific
and generic health-related QoL, as assessed by
validated tools, improved between 3 and 12 months
following acute PE in all their dimensions. Female sex,
higher BMI, and preexisting chronic cardiopulmonary
disease were associated with worse disease-specific QoL
at both 3 and 12 months. Over time, the association
with BMI became weaker, and QoL declined in older
patients and those with a history of VTE. Our data may
be relevant in the context of a more comprehensive









3 mo 12 mo 3 mo 12 mo 3 mo 12 mo
TotalAnxiety/depression intensityPain/discomfort intensity




Extreme Severe Moderate Slight No problems
Figure 4 – Distribution of generic health-related quality of life as assessed by the EuroQoL Group 5-Dimension 5-Level, dimension-specific and overall,
at 3 and 12 months. Stacked bar plots showing the percentage of patients reporting no problems, slight problems, moderate problems, or severe problems
in each one of the five dimensions of the EuroQoL Group 5-Dimension 5-Level health-related quality of life questionnaire and in the overall ques-
tionnaire at 3 months and 12 months.
2436 Original Research [ 1 5 9 # 6 CHES T J U N E 2 0 2 1 ]
Acknowledgments
Author contributions: L. V. and S. B. had
full access to the data and are guarantors of
the content of the manuscript including the
data, formal analysis and visualization. L. V.
and S. B. conceptualized the analysis and co-
wrote the original draft; M. J. contributed to
data curation and validation; E. G. and F. A.
K. provided methodologic support and
contributed to editing the manuscript; S. R.,
M. L., M. Held, F. G., L. B., R. E., M. F., J. F.,
H.-A. G., M. Halank, M. M. H., H. H. L., E.
M., F. J. M., C. N., C. O., K.-H. S., H.-J. S., F.
T., R. W., and H. W. contributed to the
investigation and data collection as well as to
reviewing and editing the manuscript; P. S.
W. provided supervision and reviewed the
manuscript; and S. V. K. supported
conceptualization and was responsible for
resource provision, supervision, and co-
writing the original draft.
Financial/nonfinancial disclosures: The
authors have reported to CHEST the
following: S. B. received lecture/consultant
fees from Bayer HealthCare, BTG
Pharmaceuticals, and LEO Pharma; and
economical support for travel/congress costs
from Daiichi Sankyo and Bayer HealthCare,
outside the submitted work. S. R. reports
remunerations for lectures and/or
consultancy from Abbott, Acceleron,
Actelion, Arena, Bayer, BMS, Ferrer,
GlaxoSmithKline, Janssen, MSD, Novartis,
Pfizer, United Therapeutics, and Vifor; and
research support to his institution from
Actelion, Bayer, Novartis, Pfizer, and United
Therapeutics. H.-A. G. has received personal
fees from Actelion, Bayer, GSK, Novartis, and
Pfizer; consultancy fees from Actelion, Bayer,
Bellerophon Pulse Technologies, Gossamer
Bio, GlaxoSmithKline, MSD, Novartis, and
Pfizer; and grants from Deutsche
Forschungsgemeinschaft. E. G. reports
research grants and speaker honoraria/
consultancy fees from Actelion, Bayer/MSD,
and GlaxoSmithKline; and research grants to
the institution from United Therapeutics,
Novartis, Bellerophon, OMT, Pfizer, and
REATA, outside the submitted work. M.
Halank has received personal fees for lectures
and consultations, for travel/accommodation
and meeting expenses from Acceleron,
Actelion, AstraZeneca, Bayer, Berlin-Chemie,
GlaxoSmithKline, Janssen-Cilag, MSD,
Novartis, and OMT, outside the submitted
work. H. H. L. received speaker honoraria/
consultancy fees from Actelion Janssen-Cilag,
Bayer, MSD, AstraZeneca, Boehringer
Ingelheim, and OMT outside the submitted
work. E. M. received speaker and/or
consulting fees from Actelion, Bayer, MSD,
and Pfizer. F. T. received travel support from
Actelion, Berlin-Chemie, Chiesi, Novartis;
and speaker or consultation fees from
Novartis and Berlin Chemie, all outside the
submitted work. S. V. K. reports institutional
grants and personal fees from Bayer AG,
Actelion/Janssen, Daiichi Sankyo, and Boston
Scientific; institutional grants from
Boehringer Ingelheim and Servier; and
personal fees from MSD and BMS/Pfizer,
outside the submitted work. None declared
(L. V., M. J., M. L., M. Held, F. G., L. B., R. E.,
M. F., J. F., M. M. H., F. A. K., F. J. M., C.
N., C. O., K.-H. S., H.-J. S., R. W., H. W., P.
S. W.).
Role of the sponsors: The authors declare
that the funders had no role in the design of
the study and collection, analysis, and
interpretation of data, and in writing the
manuscript.
Other contributions: The authors are grateful
to Kurt Quitzau, Sabrina Rump, Dorothea
Becker, PhD, and Nadine Martin, PhD, for
their contribution to the design, preparation,
and coordination of the FOCUS study and the
FOCUS BioSeq biobanking project.
Additional information: The e-Figure and e-
Tables can be found in the Supplemental
Materials section of the online article.
References
1. Keller K, Hobohm L, Ebner M, et al.
Trends in thrombolytic treatment and
outcomes of acute pulmonary embolism
in Germany. Eur Heart J. 2020;41(4):522-
529.
2. Bikdeli B, Wang Y, Jimenez D, et al.
Pulmonary embolism hospitalization,
readmission, and mortality rates in US
older adults, 1999-2015. JAMA.
2019;322(6):574-576.
3. Lehnert P, Lange T, Moller CH, Olsen PS,
Carlsen J. Acute pulmonary embolism in a
National Danish Cohort: increasing
incidence and decreasing mortality.
Thromb Haemost. 2018;118(3):539-546.
4. Jimenez D, de Miguel-Diez J, Guijarro R,
et al. Trends in the management and
outcomes of acute pulmonary embolism:
analysis from the RIETE Registry. J Am
Coll Cardiol. 2016;67(2):162-170.
5. Yang Y, Liang L, Zhai Z, et al. Pulmonary
embolism incidence and fatality trends in
Chinese hospitals from 1997 to 2008: a
multicenter registration study. PLoS One.
2011;6(11):e26861.
6. Tsai J, Grosse SD, Grant AM,
Hooper WC, Atrash HK. Trends in in-
hospital deaths among hospitalizations
with pulmonary embolism. Arch Intern
Med. 2012;172(12):960-961.
7. Barco S, Mahmoudpour SH, Valerio L,
et al. Trends in mortality related to
pulmonary embolism in the European
Region, 2000-15: analysis of vital
registration data from the WHOMortality
Database. Lancet Respir Med. 2020;8(3):
277-287.
8. Konstantinides SV, Meyer G, Becattini C,
et al. 2019 ESC guidelines for the
diagnosis and management of acute
pulmonary embolism developed in
collaboration with the European
Respiratory Society (ERS). Eur Heart J.
2020;41(4):543-603.
9. Porter ME. What is value in health care?
N Engl J Med. 2010;363(26):2477-2481.
10. Calvert M, Kyte D, Mercieca-Bebber R,
et al. Guidelines for inclusion of patient-
reported outcomes in clinical trial
protocols: the SPIRIT-PRO Extension.
JAMA. 2018;319(5):483-494.
11. Kahn SR, Akaberi A, Granton JT, et al.
Quality of life, dyspnea, and functional
exercise capacity following a first episode
of pulmonary embolism: results of the
ELOPE Cohort Study. Am J Med.
2017;130(8). 990.e999-990.e921.
12. Chuang LH, Gumbs P, van Hout B, et al.
Health-related quality of life and mortality
in patients with pulmonary embolism: a
prospective cohort study in seven
European countries. Qual Life Res.
2019;28(8):2111-2124.
13. Cohn DM, Nelis EA, Busweiler LA,
Kaptein AA, Middeldorp S. Quality of life
after pulmonary embolism: the
development of the PEmb-QoL
questionnaire. J Thromb Haemost.
2009;7(6):1044-1046.
14. Klok FA, Cohn DM, Middeldorp S, et al.
Quality of life after pulmonary embolism:
validation of the PEmb-QoL
Questionnaire. J Thromb Haemost.
2010;8(3):523-532.
15. Lapin BR. Considerations for reporting
and reviewing studies including health-
related quality of life. Chest.
2020;158(suppl 1):S49-S56.
16. van Es J, den Exter PL, Kaptein AA, et al.
Quality of life after pulmonary embolism
as assessed with SF-36 and PEmb-QoL.
Thromb Res. 2013;132(5):500-505.
17. Keller K, Tesche C, Gerhold-Ay A, et al.
Quality of life and functional limitations
after pulmonary embolism and its
prognostic relevance. J Thromb Haemost.
2019;17(11):1923-1934.
18. Klok FA, van der Hulle T, den Exter PL,
Lankeit M, Huisman MV,
Konstantinides S. The post-PE syndrome:
a new concept for chronic complications
of pulmonary embolism. Blood Rev.
2014;28(6):221-226.
19. Konstantinides SV, Barco S, Rosenkranz S,
et al. Late outcomes after acute pulmonary
embolism: rationale and design of
FOCUS, a prospective observational
multicenter cohort study. J Thromb
Thrombolysis. 2016;42(4):600-609.
20. Konstantinides SV, Torbicki A, Agnelli G,
et al. 2014 ESC guidelines on the diagnosis
and management of acute pulmonary
embolism: the Task Force for the
Diagnosis and Management of Acute
Pulmonary Embolism of the European
Society of Cardiology (ESC) Endorsed by
the European Respiratory Society (ERS).
Eur Heart J. 2014;35(43):3033-3069.
21. Frey PM, Mean M, Limacher A, et al.
Quality of life after pulmonary embolism:
prospective validation of the German
version of the PEmb-QoL questionnaire.
Thromb Res. 2015;135(6):1087-1092.
22. EuroQol Research Foundation. EQ-5D-5L
User Guide, 2019. https://euroqol.org/
publications/user-guides. Accessed March
23, 2021.
23. Klok FA, van Kralingen KW, van Dijk AP,
et al. Quality of life in long-term survivors
of acute pulmonary embolism. Chest.
2010;138(6):1432-1440.
chestjournal.org 2437
24. Stewart LK, Peitz GW, Nordenholz KE,
et al. Contribution of fibrinolysis to the
physical component summary of the SF-
36 after acute submassive pulmonary
embolism. J Thromb Thrombolysis.
2015;40(2):161-166.
25. Akaberi A, Klok FA, Cohn DM,
Hirsch A, Granton J, Kahn SR.
Determining the minimal clinically
important difference for the PEmbQoL
questionnaire, a measure of pulmonary
embolism-specific quality of life.
J Thromb Haemost. 2018;16(12):2454-
2461.
26. Klok FA, Barco S. Follow-up after acute
pulmonary embolism. Hamostaseologie.
2018;38(1):22-32.
27. Boon G, Bogaard HJ, Klok FA. Essential
aspects of the follow-up after acute
pulmonary embolism: an illustrated
review. Res Pract Thromb Haemost.
2020;4(6):958-968.
28. Klok FA, Couturaud F, Delcroix M,
Humbert M. Diagnosis of chronic
thromboembolic pulmonary
hypertension after acute pulmonary
embolism. Eur Respir J. 2020;55(6):
2000189.
29. U.S. Department of Health and Human
Services; Food and Drug Administration;
Center for Drug Evaluation and
Research (CDER); Center for Biologics
Evaluation and Research (CBER); Center
for Devices and Radiological Health
(CDRH). Draft Guidance for industry.
Patient-reported outcome measures: use
in medicinal product development to






labeling-claims. Accessed March 23,
2021.
30. European Medicines Agency. Committee
for Medicinal Products for Human Use.
Reflection paper on the regulatory
guidance for the use of health-related
quality of life (HRQL) measures in the
evaluation of medicinal products. London,
July 27, 2005. www.ema.europa.eu/en/
regulatory-guidance-use-health-related-
quality-life-hrql-measures-evaluation-
medicinal-products. Accessed March 23,
2021.
31. Cohen AT, Gitt AK, Bauersachs R, et al.
The management of acute venous
thromboembolism in clinical practice.
Results from the European PREFER in
VTE Registry. Thromb Haemost.
2017;117(7):1326-1337.
2438 Original Research [ 1 5 9 # 6 CHES T J U N E 2 0 2 1 ]
